Patents Assigned to Biopharm Gesellschaft zur Biotechnologischen Entwicklung von
Pharmaka mbH
-
Publication number: 20090155366Abstract: The present invention concerns improved osteoinductive materials comprising matrix materials and morphogenetic roteins, wherein depending on the subject matter the proteins may be dimeric or monomeric proteins. The osteoinductive materials according to the present invention have improved properties. The invention further concerns methods for producing the respective improved osteoinductive materials.Type: ApplicationFiled: December 17, 2008Publication date: June 18, 2009Applicant: Biopharm Gesellschaft zur Biotechnologischen Entwicklung von Pharmaka MbHInventors: Jens POHL, Rolf Bechtold, Michael Kruse
-
Patent number: 7485617Abstract: The present invention concerns improved osteoinductive materials comprising matrix materials and morphogenetic roteins, wherein depending on the subject matter the proteins may be dimeric or monomeric proteins. The osteoinductive materials according to the present invention have improved properties. The invention further concerns methods for producing the respective improved osteoinductive materials.Type: GrantFiled: March 26, 2004Date of Patent: February 3, 2009Assignee: Biopharm Gesellschaft zur Biotechnologischen Entwicklung von Pharmaka mbHInventors: Jens Pohl, Rolf Bechtold, Michael Kruse
-
Publication number: 20080318860Abstract: The application relates to novel biosynthetic growth factor mutants, derived from GDF-5, which exhibit improved biological activity. Mutations at positions 453 and 456 of human GDF-5 are disclosed, as well as use of these mutants in therapy of diseases associated with tissue degeneration/destruction.Type: ApplicationFiled: November 17, 2006Publication date: December 25, 2008Applicant: Biopharm Gesellschaft zur biotechnologischen Entwicklung von pharmaka mbHInventors: Jens Pohl, Frank Ploger, Michael Kruse
-
Publication number: 20080318856Abstract: This invention provides for a protein of the TGF-? superfamily in which the cysteine involved in the normal formation of homodimers is changed to another amino acid. These mutant proteins, as monomers, display higher bone morphogenetic activity than the wild-type protein dimers. Also provided is a method for producing and isolating these monomers by plasmid driven expression in various host systems including E. coli. In addition, the invention discloses the use of an agent containing purified monomers in preventing and treating diseases and problems affecting bone and/or cartilage.Type: ApplicationFiled: June 6, 2007Publication date: December 25, 2008Applicant: Biopharm Gesellschaft zur biotechnologischen Entwicklung von Pharmaka mbHInventors: Shinji KAWAI, Michio KIMURA, Yoshifumi MURAKI, Mieko KATSUURA
-
Patent number: 7365051Abstract: The present invention concerns a bioactive implant material having a cartilage-inducing and/or bone-inducing activity composed of two components A and B, of which A is a bone-inducing and/or cartilage-inducing protein or protein mixture and preferably one or several proteins from the TGF-? superfamily, preferably MP52 or a DNA sequence coding therefor and B is a carrier matrix composed of calcium phosphate ceramics with an interconnecting microporosity which already alone has bone-inducing properties. The invention additionally concerns the production of these compounds and their use for the treatment of diseases which affect cartilage and/or bones as well as to treat damage to cartilage and/or bone tissue.Type: GrantFiled: March 16, 2005Date of Patent: April 29, 2008Assignee: Biopharm Gesellschaft zur Biotechnologischen Entwicklung von Pharmaka mbHInventors: Michael Paulista, Jens Pohl, Joachim Pabst, Helmut Heide
-
Patent number: 7238657Abstract: A cartilage and bone morphogenetic repairing composition which contains a bone morphogenetic protein and a polyoxyethylene-polyoxypropylene glycol is disclosed. It is preferable that the molecular weight of a polyoxypropylene, i.e., a component of said polyoxyethylene-polyoxypropylene glycol, is in the range of about 1,500-4,000 and the weight ratio of ethylene oxide is in the range of 40-80%/molecule, and a concentration of said polyoxyethylene-polyoxypropylene glycol in an aqueous solution is about 10-50%. The composition may be applied in a cartilage and bone morphogenetic method without a surgical operation and comprises a bone morphogenetic protein and a carrier which has a high bio-absorption, a good affinity to the bone morphogenetic protein and is capable of temperature dependent gel-sol reversible transition. The composition may conveniently be applied locally to the site of a bone fracture or bone defect.Type: GrantFiled: July 7, 2004Date of Patent: July 3, 2007Assignee: Biopharm Gesellschaft zur Biotechnologischen Entwicklung Von Pharmaka mbHInventors: Takesada Shimura, Satsuki Toriyama
-
Patent number: 7235241Abstract: This invention provides for a protein of the TGF-? superfamily in which the cysteine involved in the normal formation of homodimers is changed to another amino acid. These mutant proteins, as monomers, display higher bone morphogenetic activity than the wild-type protein dimers. Also provided is a method for producing and isolating these monomers by plasmid driven expression in various host systems including E. coli. In addition, the invention discloses the use of an agent containing purified monomers in preventing and treating diseases and problems affecting bone and/or cartilage.Type: GrantFiled: January 6, 2004Date of Patent: June 26, 2007Assignee: Biopharm Gesellschaft zur biotechnologischen Entwicklung von Pharmaka mbHInventors: Shinji Kawai, Michio Kimura, Yoshifumi Muraki, Mieko Katsuura
-
Publication number: 20070031351Abstract: The invention provides DNA sequences encoding novel members of the TGF-? family of proteins. The. TGF-? family comprises proteins which function as growth and/or differentiation factors and which are useful in medical applications. Accordingly, the invention also describes the isolation of the above-mentioned DNA sequences, the expression of the encoded proteins, the production of said proteins and pharmaceutical compositions containing said proteins.Type: ApplicationFiled: October 11, 2006Publication date: February 8, 2007Applicant: BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA MBHInventors: Gertrud Hoetten, Helge Neidhardt, Rolf Bechtold, Jens Pohl
-
Patent number: 7141239Abstract: The invention provides DNA sequences encoding novel members of the TGF-? family of proteins. The TGF-? family comprises proteins which function as growth and/or differentiation factors and which are useful in medical applications. Accordingly, the invention also describes the isolation of the above-mentioned DNA sequences, the expression of the encoded proteins, the production of said proteins and pharmaceutical compositions containing said proteins.Type: GrantFiled: April 14, 2005Date of Patent: November 28, 2006Assignee: Biopharm Gesellschaft zur Biotechnologischen Entwicklung von Pharmaka mbHInventors: Gertrud Hötten, Helge Neidhardt, Rolf Bechtold, Jens Pohl
-
Patent number: 7132397Abstract: The purpose is to provide a mature protein having an antagonistic activity against bone morphogenetic proteins. The mature protein having an antagonistic activity against bone morphogenetic proteins is obtained by converting at least one residue among methionine residues or tryptophane residues existing in the amino acid sequence of mature human MP52 (SEQ ID No 1) to a hydrophilic residue by chemical modification, or replacing said residues with a hydrophilic amino acid residue or a polar amino acid residue. The chemical modification for said methionine residue is performed by an oxidization reaction or an alkylation reaction. The chemical modification for said tryptophane residue is performed by an allylsulphenylation reaction.Type: GrantFiled: October 4, 1999Date of Patent: November 7, 2006Assignee: Biopharm Gesellschaft zur biotechnologischen Entwicklung von Pharmaka mbHInventors: Mieko Katsuura, Michio Kimura
-
Patent number: 7129054Abstract: The invention relates to an antibody or antibody fragment which specifically binds to a protein of the TGF-? family. The invention also relates to a kit for detecting a protein of the TGF-? family which comprises the antibody or antibody fragment. Finally, the invention relates to method for detecting a protein of the TGF-? family which uses the antibody or antibody fragment.Type: GrantFiled: May 19, 2005Date of Patent: October 31, 2006Assignee: Biopharm Gesellschaft zur Biotechnologischen Entwicklung von Pharmaka mbHInventors: Gertrud Hötten, Helge Neidhardt, Rolf Bechtold, Jens Pohl, Michael Paulista
-
Patent number: 7067637Abstract: The invention provides antibody and antibody fragments which specifically bind to novel members of the TGF-? family of proteins. The TFG-? family comprises proteins which function as growth and/or differentiation factors and which are useful in medical applications. Accordingly, the invention also applies to the production of said antibodies or antibody fragments and a diagnostic method for detecting said proteins of the TGF-? family.Type: GrantFiled: September 24, 1999Date of Patent: June 27, 2006Assignee: BioPharm Gesellschaft zur Biotechnologischen Entwicklung von Pharmaka mbHInventors: Gertrud Hötten, Helge Neidhardt
-
Patent number: 7025959Abstract: The invention concerns a protein of the TGF-? family, the DNA coding therefor and a pharmaceutical composition containing such protein.Type: GrantFiled: October 10, 2000Date of Patent: April 11, 2006Assignee: Biopharm Gesellschaft Zur Biotechnologischen Entwicklung von Pharmaka mbHInventors: Gertrud Hötten, Helge Neidhardt, Rolf Bechtold, Jens Pohl, Michael Paulista
-
Publication number: 20050175553Abstract: The invention provides DNA sequences encoding novel members of the TGF-? family of proteins. The TGF-? family comprises proteins which function as growth and/or differentiation factors and which are useful in medical applications. Accordingly, the invention also describes the isolation of the above-mentioned DNA sequences, the expression of the encoded proteins, the production of said proteins and pharmaceutical compositions containing said proteins.Type: ApplicationFiled: April 14, 2005Publication date: August 11, 2005Applicant: BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA MBHInventors: Gertrud Hotten, Helge Neidhardt, Rolf Bechtold, Jens Pohl
-
Publication number: 20050169965Abstract: The present invention concerns a bioactive implant material having a cartilage-inducing and/or bone-inducing activity composed of two components A and B, of which A is a bone-inducing and/or cartilage-inducing protein or protein mixture and preferably one or several proteins from the TGF-? superfamily, preferably MP52 or a DNA sequence coding therefor and B is a carrier matrix composed of calcium phosphate ceramics with an interconnecting microporosity which already alone has bone-inducing properties. The invention additionally concerns the production of these compounds and their use for the treatment of diseases which affect cartilage and/or bones as well as to treat damage to cartilage and/or bone tissue.Type: ApplicationFiled: March 16, 2005Publication date: August 4, 2005Applicant: Biopharm Gesellschaft zur biotechnologischen Entwicklung von Pharmaka mbHInventors: Michael Paulista, Jens Pohl, Joachim Pabst, Helmut Heide
-
Patent number: 6903071Abstract: A cartrilage and bone morphogenetic repairing composition comprising a collagen-free aqueous solution of a polyoxyethylene-polyoxypropylene and an effective amount of a bone morphogenetic protein, the molecular weight of polyoxypropylene as a constituent of said polyoxyethylene-polyoxypropylene molecular is 900 to 4,000 in a unit of Dalton (D) and the ethylene oxide content is 5 to 90% by weight of the polyoxyethylene-propoxypropylene molecule whereby the solution is liquid at 1 to 30° C. and gelatinizes at about 37° C. and a method of using the same.Type: GrantFiled: November 14, 1996Date of Patent: June 7, 2005Assignee: Biopharm Gesellschaft zur Biotechnologischen Entwicklung von Pharmaka mbHInventors: Takesada Shimura, Satsuki Toriyama
-
Publication number: 20050013864Abstract: A cartilage and bone morphogenic repairing material which contains a bone morphogenic protein and a polyoxyethylene-polyoxypropylene glycol. In particular, it is preferable that a molecular weight of a polyoxypropylene, i.e., a component of said polyoxyethylene-polyoxypropylene glycol, is in the range of about 1,500-4,000 and a weight ratio of ethylene oxide is in the range of 40-80%/molecule, and a concentration of said polyoxyethylene-polyoxypropylene glycol in an aqueous solution is about 10-50%. It may be applied in a cartilage and bone morphogenic method requiring no surgical operation and which comprises a bone morphogenic protein and a carrier having a high bio-absorption, a good affinity to the bone morphogenic protein and capable of temperature dependent gel-sol reversible transition. It is convenient to apply locally to the site of a bone fracture or bone defect with an efficient treatment effect.Type: ApplicationFiled: July 7, 2004Publication date: January 20, 2005Applicant: Biopharm Gesellschaft zur Biotechnologischen Entwicklung von Pharmaka mbHInventors: Takesada Shimura, Satsuki Toriyama
-
Patent number: 6790824Abstract: The present invention relates to a pharmaceutical composition having neurotrophic activity, comprising a biologically active amount of at least two cytokines, wherein at least one of said cytokines is BMP, GDF, TGF-&bgr; or GDNF.Type: GrantFiled: March 17, 2000Date of Patent: September 14, 2004Assignee: Biopharm Gesellschaft zur biotechnologischen Entwicklung von Pharmaka mbHInventors: Klaus Unsicker, Jens Pohl, Michael Paulista, Rolf Bechtold
-
Publication number: 20040146979Abstract: The invention concerns a protein of the TGF-&bgr; family, the DNA coding therefor and a pharmaceutical composition containing the protein.Type: ApplicationFiled: March 16, 2004Publication date: July 29, 2004Applicant: Biopharm Gesellschaft zur Biotechnologischen Entwicklung von Pharmaka mbHInventors: Gertrud Hotten, Helge Neidhardt, Michael Paulista
-
Patent number: 6764994Abstract: The invention concerns a protein of the TGF-&bgr; family, the DNA coding therefor and a pharmaceutical composition containing the protein.Type: GrantFiled: August 31, 1999Date of Patent: July 20, 2004Assignee: Biopharm Gesellschaft zur biotechnologischen Entwicklung von Pharmaka mbHInventors: Gertrud Hötten, Helge Neidhardt, Michael Paulista